Home » Stocks » ALZN

Alzamend Neuro, Inc. (ALZN)

Stock Price: $9.03 USD -1.06 (-10.51%)
Updated Jun 18, 2021 4:00 PM EDT - Market closed
After-hours: $8.89 -0.14 (-1.55%) Jun 18, 7:59 PM
Market Cap 742.83M
Revenue (ttm) n/a
Net Income (ttm) -5.05M
Shares Out 82.26M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 18
Last Price $9.03
Previous Close $10.09
Change ($) -1.06
Change (%) -10.51%
Day's Open 9.99
Day's Range 8.61 - 10.47
Day's Volume 394,175
52-Week Range 8.61 - 33.55


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #ADDF--Alzamend Neuro Announces Closing of Initial Public Offering & Full Exercise of Underwriter's Over-allotment Option for Gross Proceeds of $14.4 Million

3 days ago - Business Wire

LAS VEGAS--(BUSINESS WIRE)---- $AGH #AP--Ault Global Holdings Announces Alzamend Neuro (Nasdaq: ALZN) Pricing of Initial Public Offering of 2,500,000 Shares of Common Stock at $5.00 per Share

Other stocks mentioned: DPW
4 days ago - Business Wire

TAMPA, Fla.--(BUSINESS WIRE)---- $AMEX #ADDF--Alzamend Neuro Announces Pricing of Initial Public Offering of 2,500,000 Shares of its Common Stock at a Price to the Public of $5.00 per Share

6 days ago - Business Wire

Alzamend Neuro, Inc. has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About ALZN

Alzamend Neuro is a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. With our two current and future product candidates, we aim to bring treatments or cures to market at a reasonable cost as quickly as possible. Our primary target is Alzheimer’s disease. Existing Alzheimer’s treatments only temporarily relieve symptoms but do not slow or halt the underlying worsening of the disease, which currently affects roughly 6.2 million Americans... [Read more...]

IPO Date
Jun 15, 2021
Stephan Jackman
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements